Publications by authors named "T SHIMOYAMA"
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.
View Article and Find Full Text PDFBackground: Infarct volume on diffusion-weighted imaging (DWI) is a promising imaging marker for clinical outcomes in patients with acute stroke treated with mechanical thrombectomy (MT), but its predictive value has not been well evaluated, especially in consecutive patients. The present study aimed to elucidate the relationship between infarct volume and its change and favorable functional outcomes in consecutive patients with acute stroke who underwent MT.
Method: Of patients with consecutive acute stroke who underwent MT from September 2014 through December 2019, those who were pre-morbidly independent were enrolled.
Article Synopsis
- Significant advancements in chemotherapy for advanced gastric cancer, focusing on biomarker-specific drugs for HER2-positive patients and those with microsatellite instability-high (MSI-H).
- A rare case of a 75-year-old man with HER2-positive and MSI-H gastric cancer showed remarkable tumor shrinkage after treatment with S-1, oxaliplatin, and trastuzumab.
- Following effective chemotherapy, the patient underwent successful conversion surgery, achieving a complete pathological response and remaining recurrence-free for seven months.
Functional dyspepsia is distinguishable from -associated dyspepsia. However, distinguishing -associated dyspepsia from functional dyspepsia before eradication is difficult. Therefore, in the present study, we aimed to investigate whether serum pepsinogen levels before eradication are associated with the amelioration of dyspepsia after successful eradication.
View Article and Find Full Text PDFArticle Synopsis
- Patients on hemodialysis (HD) are at risk for gastrointestinal diseases, and while eliminating Helicobacter pylori is advised to prevent gastric cancer, the best treatment approach and dosages for these patients remain unclear due to potential side effects and renal risks.
- Some drugs used in eradication therapy, especially amoxicillin, can worsen kidney function, necessitating careful adjustment of dosages in HD patients.
- Recent studies show that reducing drug dosages by 1/2 to 1/3 can minimize adverse effects while maintaining similar rates of successful eradication compared to healthy individuals, highlighting the need for optimized treatment regimens for this population.